O
Olema Oncology
Developing therapies that offer the potential to improve outcomes for women living with cancer
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation targeted therapies for women's cancers.
Its lead product candidate, palazestrant (OP-1250), is a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being developed for the treatment of ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
The company is also developing a KAT6 inhibitor program, which is in the preclinical stage. Olema is conducting a Phase 3 clinical trial of palazestrant in combination with CDK4/6 inhibitors in patients with advanced or metastatic ER+/HER2- breast cancer.
Olema has a clinical trial collaboration and supply agreement with Novartis to evaluate palazestrant in combination with Novartis' CDK4/6 inhibitor ribociclib and mTOR inhibitor everolimus in patients with ER+/HER2- advanced or metastatic breast cancer.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- San Francisco, United States
- Listing
- IPO 2020
- Employees
- 156
- Open positions
- 14
- Dealroom signal
- 90.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Feb 2026 | $69M | — | Cormorant Asset Management | ↗ |
| PRIVATE PLACEMENT VCOther financing | Dec 2024 | $250M | — | Bain Capital Life Sciences · Paradigm BioCapital · Wellington Management · Adage Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$178M | — |
| 2025 | $0 | — | −$178M | — |
| 2024 | $0 | — | −$142M | — |
| 2023 | $0 | — | −$105M | — |
| 2022 | $0 | — | −$107M | — |
| 2021 | $0 | — | −$71M | — |
| 2020 | $0 | — | −$21M | — |
Growth signals
Latest recorded traffic for Olema Oncology is 6.5K monthly website visits, down 32.3% over the last three months. Olema Oncology's team grew 6.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
BVF Partners
Series B and later14 investors entered at this stage
Venrock
Wellington Management
BlackRock
Foresite Capital
Vivo Capital
Cormorant Asset Management
RA Capital Management
Janus Henderson Investors
Logos Capital
Avoro Capital Advisors
OrbiMed
Citadel
Deerfield
Silicon Valley Bank
Other known investors7 additional known investors
Paradigm BioCapital
Woodline Partners
Adage Capital
Bain Capital Life Sciences
Deep Track Capital
Driehaus Capital Management
Lightspeed Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Olema Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Olema Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.